Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073)
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Who can join: Review the eligibility criteria below.
Location: ArriVent Investigative Site — Prescott, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (42 Sites)
Showing the first 25 of 42 sites.
- ArriVent Investigative Site — Prescott, Arizona
- ArriVent Investigative Site — Sacramento, California
- ArriVent Investigative Site — Whittier, California
- ArriVent Investigative Site — Celebration, Florida
- ArriVent Investigative Site — Detroit, Michigan
- ArriVent Investigative Site — Houston, Texas
- ArriVent Investigative Site — Fairfax, Virginia
- ArriVent Investigative Site — Blacktown, New South Wales
- ArriVent Investigative Site — St Leonards, New South Wales
- ArriVent Investigative Site — Heidelberg, Victoria
- Arrivent Investigative Site — Edmonton,
- Arrivent Investigative Site — Toronto,
- Allist Investigative Site — Hefei, Anhui
- Allist Investigative Site — Beijing, Beijing Municipality
- Allist Investigative Site — Chaoyang, Beijing Municipality
- Allist Investigative Site — Chongqing, Chongqing Municipality
- Allist Investigative Site — Harbin, Heilongjiang
- Allist Investigative Site — Zhengzhou, Henan
- Allist Investigative Site — Zhengzhou, Henan
- Allist Investigative Site — Wuhan, Hubei
- Allist Investigative Site — Xuzhou, Jiangsu
- Allist Investigative Site — Nanchang, Jianxi
- Allist Investigative Site — Changchun, Jilin
- Allist Investigative Site — Jinan, Shandong
- Allist Investigative Site — Jinan, Shandong
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-Small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.